enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Prostate cancer - Wikipedia

   en.wikipedia.org/wiki/Prostate_cancer

   Eventually cancer cells can grow resistant to this treatment. This most-advanced stage of the disease, called castration-resistant prostate cancer, is treated with continued hormone therapy alongside the chemotherapy drug docetaxel. Some tumors metastasize (spread) to other areas of the body, particularly the bones and lymph nodes.

3. Management of prostate cancer - Wikipedia

   en.wikipedia.org/wiki/Management_of_prostate_cancer

   Abiraterone acetate was FDA approved in April 2011 for treatment of castration-resistant prostate cancer for patients who have failed docetaxel therapy. Abiraterone acetate inhibits an enzyme known as CYP17, which is used in the body to produce testosterone.

4. DU145 - Wikipedia

   en.wikipedia.org/wiki/DU145

   Castration-resistant prostate cancer (CRPC) is prostate cancer that progresses despite extremely low testosterone in the body often due to medical castration. [4] Unlike many other types of prostate cancer, CRPC do not need normal testosterone levels, but they still require regular androgen receptors (AR).

5. Cabazitaxel - Wikipedia

   en.wikipedia.org/wiki/Cabazitaxel

   In a phase III trial with 755 men for the treatment of castration-resistant prostate cancer, median survival was 15.1 months for participants receiving cabazitaxel versus 12.7 months for participants receiving mitoxantrone. Cabazitaxel was associated with more grade 3–4 neutropenia (81.7%) than mitoxantrone (58%). [13]

6. Prostate cancer shouldn’t be a death sentence. But for a ...

   www.aol.com/finance/prostate-cancer-shouldn-t...

   In fact, the five-year survival rate for prostate cancer detected early is virtually 100%, Siddiqui says. The outlook for late-diagnosed patients, however, is not nearly as rosy.

7. Tasquinimod - Wikipedia

   en.wikipedia.org/wiki/Tasquinimod

   Tasquinimod has been mostly studied in prostate cancer, but its mechanism of action suggests that it could be used to treat other cancers. Castration-resistant prostate cancer (CRPC), formerly called hormone-resistant or hormone-refractory prostate cancer, is prostate cancer that grows despite medical or surgical androgen deprivation therapy.